The stock of InflaRx N.V. (NASDAQ:IFRX) is a huge mover today! The stock decreased 5.95% or $0.195 during the last trading session, reaching $3.085. About 2.77M shares traded or 145.09% up from the average. InflaRx N.V. (NASDAQ:IFRX) has risen 20.54% since June 11, 2018 and is uptrending. It has outperformed by 16.11% the S&P500.
The move comes after 9 months negative chart setup for the $80.10 million company. It was reported on Jun, 11 by Barchart.com. We have $2.93 PT which if reached, will make NASDAQ:IFRX worth $4.01M less.
Analysts await InflaRx N.V. (NASDAQ:IFRX) to report earnings on August, 8. They expect $-0.54 EPS, down 350.00 % or $0.42 from last year’s $-0.12 per share. After $-0.43 actual EPS reported by InflaRx N.V. for the previous quarter, Wall Street now forecasts 25.58 % negative EPS growth.
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Nasdaq.com which released: “Pre-Market Most Active for May 6, 2019 : SQQQ, APC, TVIX, OVID, AMD, QQQ, NIO, AAPL, BABA, OXY, GE, F – Nasdaq” on May 06, 2019, also Globenewswire.com with their article: “InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa – GlobeNewswire” published on February 06, 2019, Nasdaq.com published: “Mid-Afternoon Market Update: Dow Rises 170 Points; Pivotal Software Shares Plunge – Nasdaq” on June 05, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Nasdaq.com and their article: “Pre-Market Most Active for Jun 5, 2019 : IFRX, AMD, QQQ, GME, NOK, SIEN, AAPL, TVIX, PVTL, SNAP, NIO, ACB – Nasdaq” published on June 05, 2019 as well as Seekingalpha.com‘s news article titled: “InflaRx Tanks 91.79% As IFX-1 Phase II Trial Flops, Provides Bargain Buy For Competitor ChemoCentryx – Seeking Alpha” with publication date: June 08, 2019.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $80.10 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.